ATE230987T1 - Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast - Google Patents

Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast

Info

Publication number
ATE230987T1
ATE230987T1 AT96916361T AT96916361T ATE230987T1 AT E230987 T1 ATE230987 T1 AT E230987T1 AT 96916361 T AT96916361 T AT 96916361T AT 96916361 T AT96916361 T AT 96916361T AT E230987 T1 ATE230987 T1 AT E230987T1
Authority
AT
Austria
Prior art keywords
pranlukast
granula
producing
adhesiveness
containing granules
Prior art date
Application number
AT96916361T
Other languages
English (en)
Inventor
Seiei Sasatani
Masashi Shiota
Yoshinori Ii
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE230987T1 publication Critical patent/ATE230987T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT96916361T 1995-06-12 1996-06-11 Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast ATE230987T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16929295 1995-06-12
PCT/JP1996/001578 WO1996041628A1 (en) 1995-06-12 1996-06-11 Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast

Publications (1)

Publication Number Publication Date
ATE230987T1 true ATE230987T1 (de) 2003-02-15

Family

ID=15883819

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916361T ATE230987T1 (de) 1995-06-12 1996-06-11 Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast

Country Status (8)

Country Link
US (1) US5876760A (de)
EP (1) EP0834314B1 (de)
KR (1) KR100389606B1 (de)
AT (1) ATE230987T1 (de)
DE (1) DE69625813T2 (de)
DK (1) DK0834314T3 (de)
ES (1) ES2191101T3 (de)
WO (1) WO1996041628A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19617487A1 (de) † 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
TW546151B (en) 1997-07-23 2003-08-11 Senju Pharma Co Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
ATE228823T1 (de) * 1998-04-18 2002-12-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
KR100381834B1 (ko) * 2000-05-20 2003-04-26 이상득 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
US6692976B1 (en) * 2000-08-31 2004-02-17 Agilent Technologies, Inc. Post-etch cleaning treatment
CN101022796B (zh) * 2004-07-14 2013-02-27 炎症研究中心有限公司 抑制肿瘤转移的方法
KR100591786B1 (ko) 2004-10-19 2006-06-26 휴먼팜 주식회사 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
KR101086254B1 (ko) * 2004-11-04 2011-11-24 에스케이케미칼주식회사 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
KR100957731B1 (ko) * 2005-04-11 2010-05-12 오노 야꾸힝 고교 가부시키가이샤 쓴맛이 저감된 프란루카스트 수화물을 함유하는 제제
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
KR101233235B1 (ko) * 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
KR100715355B1 (ko) 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
KR100981751B1 (ko) * 2005-10-28 2010-09-10 주식회사유한양행 프란루카스트를 함유하는 과립 및 그의 제조방법
KR100981750B1 (ko) * 2005-10-28 2010-09-10 주식회사유한양행 분무-건조 과립 및 그의 제조방법
BRPI0720472A2 (pt) * 2006-12-22 2014-01-14 Yuhan Corp Dispersão sólida contendo revaprazan e processo para a preparação da mesma
KR102363727B1 (ko) 2015-06-01 2022-02-16 삼아제약 주식회사 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법
CN116270902B (zh) * 2023-04-26 2024-08-20 南京同仁堂药业有限责任公司 一种颈舒颗粒及其制备方法
KR20240164596A (ko) 2023-05-09 2024-11-20 삼아제약 주식회사 복약편의성이 증진된 프란루카스트 함유 약제학적 조성물
KR102840220B1 (ko) 2023-07-18 2025-07-31 삼아제약 주식회사 프란루카스트 함유 약제학적 조성물의 제조방법 및 상기 제조방법에 의해 제조된 약제학적 조성물
KR20250052834A (ko) 2023-10-12 2025-04-21 주식회사 다산제약 프란루카스트의 생체이용률이 개선된 약제학적 조성물 및 그 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994458A (en) * 1990-04-30 1991-02-19 Basf Corporation Process for rotary fluid bed granulation of riboflavin
EP0641569A4 (de) * 1992-03-12 1997-01-29 Ono Pharmaceutical Co Antipruritisches agens.
JPH0776516A (ja) * 1993-09-06 1995-03-20 Toyobo Co Ltd 難溶性薬物含有製剤の製造方法

Also Published As

Publication number Publication date
EP0834314A4 (de) 2000-05-10
US5876760A (en) 1999-03-02
KR100389606B1 (ko) 2003-09-26
WO1996041628A1 (en) 1996-12-27
KR19990022791A (ko) 1999-03-25
DE69625813T2 (de) 2003-09-04
EP0834314B1 (de) 2003-01-15
ES2191101T3 (es) 2003-09-01
DK0834314T3 (da) 2003-02-24
EP0834314A1 (de) 1998-04-08
DE69625813D1 (de) 2003-02-20

Similar Documents

Publication Publication Date Title
ATE230987T1 (de) Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
PT797987E (pt) Preparacao granular de libertacao controlada e processo para a sua preparacao
ATE323467T1 (de) Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten
MY105047A (en) Process for making concentrated surfactant granules.
AU4913500A (en) Method for producing bead polymers
CA2268626A1 (en) Pharmaceutical composition for rapid suspension in aqueous media
AU636392B2 (en) Artificial stone compositions, process of producing the same and apparatus employed in the production thereof
TW343199B (en) Process for the production of a cellulose suspension
CA2196303A1 (en) Production of anionic surfactant granules
ATE195001T1 (de) Herstellung und verwendung von diacylperoxid enthaltende kompositteilchen
DE3160522D1 (en) Agents for the detection of esterolytic and/or proteolytic enzymes; and phenoxy-amino acids and phenoxy-peptide esters suitable as substrates therefor, process for their production and their use in producing the agents
ATE216576T1 (de) Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen
NO894689L (no) Fremgangsmaate for fremstilling av blekende granulat.
HUP9900808A2 (hu) Eljárás nukleozid-5'-foszfát-észterek előállítására
MX9801940A (es) Composiciones que comprenden particulas de silice hidrofilica.
HUP9601358A3 (en) Fluoro-phenyl-substituted alkenyl-carboxylic-guanidines, process for producing them, their use as medicines or diagnostica, and pharmaceutical compositions containing them
TW355185B (en) Process for producing a matrix pigment particle of a colored lake or dye and matrix pigment particle produced therefrom the invention relates to a process for producing a matrix pigment particle particularly useful in toothpaste formulations
ATE207528T1 (de) Verfahren zur herstellung von waschmittelrohstoffen
HU9601321D0 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, their use as pharmaceutical compositions or diagnostica, and pharmaceutical compositions containing them
IE892100L (en) Process for making concentrated surfactant granules
EP0162465A3 (de) Verbindungen verwendet in Parfüms
CA2071707A1 (en) Polymer Alloy Material and Process for Production Thereof
DE69926223D1 (de) Verfahren zur herstellung von zwischenprodukten
ATE269399T1 (de) Verfahren zur herstellung teilchenförmiger wasch- oder reinigungsmittel
GR3026341T3 (en) Amorphous alkali metal silicate, process and uses.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0834314

Country of ref document: EP

REN Ceased due to non-payment of the annual fee